Patients with inflammatory conditions and concomitant cirrhosis who are treated with tumor necrosis factor inhibitors face heightened risk of serious infections and other complications, according to new Cleveland Clinic research.
A case reminding physicians that rare conditions should be kept in the differential diagnosis of unusual presentations.
By now most rheumatologists are aware that checkpoint inhibitors are capable of unleashing a wide array of autoimmune and autoinflammatory adverse events within virtually every organ system. These complications have posed new challenges to all practitioners.
As advances in genomic medicine improve the diagnosis of autoinflammatory disease and help us recognize new disorders in this class, the need for coordinated care intensifies.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Children with recurrent fevers could have an infection, a malignancy or a rheumatologic disease. A comprehensive center at Cleveland Clinic specializes in the evaluation, treatment and management of these young patients.